Sanmamed et al. [84, 85], evaluated the relationship between changes in the serum interleukin-8 (IL-8) levels, an immunomodulating chemokine produced also by tumor cells [86], and the response to immunotherapy in melanoma and NSCLC patients. This evidence concerns the gene CXCL8 and neoplasm.